Literature DB >> 20234310

Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology.

Hiroshi Sunaga1, Jaideep K Malhotra, Edward Yoon, John J Savarese, Paul M Heerdt.   

Abstract

BACKGROUND: CW002 is a neuromuscular blocking drug that is inactivated by endogenous L-cysteine. This study determined the exogenous L-cysteine dose-response relationship for CW002 reversal along with acute cardiovascular effects and organ toxicity in dogs.
METHODS: Six dogs were each studied four times during isoflurane-nitrous oxide anesthesia and recording of muscle twitch, arterial pressure, and heart rate. CW002 (0.08 mg/kg or 9 x ED95) was injected, and the time to spontaneous muscle recovery was determined. CW002 was then administered again followed 1 min later by 10, 20, 50, or 100 mg/kg L-cysteine (1 dose/experiment). After twitch recovery, CW002 was given a third time to determine whether residual L-cysteine influenced duration. Preliminary toxicology was performed in an additional group of dogs that received CW002 followed by vehicle (n = 8) or 200 mg/kg L-cysteine (n = 8). Animals were awakened and observed for 2 or 14 days before sacrificing and anatomic, biochemical, and histopathologic analyses.
RESULTS: L-cysteine at all doses accelerated recovery from CW002, with both 50 and 100 mg/kg decreasing median duration from more than 70 min to less than 5 min. After reversal, duration of a subsequent CW002 dose was also decreased in a dose-dependent manner. Over the studied dose range, L-cysteine had less than 10% effect on blood pressure and heart rate. Animals receiving a single 200-mg/kg dose of L-cysteine showed no clinical, anatomic, biochemical, or histologic evidence of organ toxicity.
CONCLUSION: The optimal L-cysteine dose for rapidly reversing the neuromuscular blockade produced by a large dose of CW002 in dogs is approximately 50 mg/kg, which has no concomitant hemodynamic effect. A dose of 200 mg/kg had no evident organ toxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234310     DOI: 10.1097/ALN.0b013e3181d31f8c

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  4 in total

Review 1.  [Update on muscle relaxation : What comes after succinylcholine, rocuronium and sugammadex?]

Authors:  N Zoremba; G Schälte; C Bruells; F K Pühringer
Journal:  Anaesthesist       Date:  2017-05       Impact factor: 1.041

2.  Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers.

Authors:  Josh D Kaullen; Joel S Owen; Kim L R Brouwer; Paul M Heerdt; Cynthia A Lien; John J Savarese; Virginia D Schmith
Journal:  Anesthesiology       Date:  2018-06       Impact factor: 7.892

3.  Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits.

Authors:  Leslie L Diaz; Jingwei Zhang; Paul M Heerdt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

Review 4.  New Drug Developments for Neuromuscular Blockade and Reversal: Gantacurium, CW002, CW011, and Calabadion.

Authors:  Hans Donald de Boer; Ricardo Vieira Carlos
Journal:  Curr Anesthesiol Rep       Date:  2018-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.